AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18046027
Drug: Eltrombopag 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 30 mg
Trial: 20735290
Drug: Eltrombopag 75
RxNorm normalized name: eltrombopag 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 75 mg
Trial: 10443608
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg rectal acetaminophen
Trial: 10443608
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg rectal acetaminophen
Trial: 8543705
Drug: Nonbehavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonbehavioral treatment
Trial: 7437240
Drug: Lignocaine (L)
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lignocaine (L)
Trial: 25556611
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) 100-800 μg
Trial: 21829747
Drug: Gatifloxacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin (10 mg/kg/day for 3 days)
Trial: 21829747
Drug: Ciprofloxacin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (30 mg/kg/day for 3 days in two divided doses)
Trial: 17378192
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) at Houxi (SI 3), treated once daily for 3 sessions (1 course)
Trial: 17378192
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group with Mobike, 7.5 mg once daily
Trial: 17010857
Drug: Aspiration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration of lens epithelial cells (LECs) from under the anterior capsule
Trial: 10522582
Drug: Combined diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined diltiazem (0.2 mg x kg(‐1)) and lidocaine (1.0 mg x kg(‐1))
Trial: 10522582
Drug: Diltiazem (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.2 mg x kg(‐1))
Trial: 10522582
Drug: Lidocaine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.0 mg x kg(‐1))
Trial: 8542008
Drug: Prednisone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (2 mg/kg to a maximum of 60 mg)
Trial: 1931867
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma insulin tertile 1
Trial: 1931867
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma insulin tertile 2
Trial: 1931867
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma insulin tertile 3
Trial: 7046104
Drug: Amoxycillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanic acid (A-CA) 250 mg/125 mg, taken 3 times daily for 7 days
Trial: 7046104
Drug: Amoxycillin 250
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 250 mg capsules, taken 3 times daily for 7 days
Trial: 7046104
Drug: Amoxycillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanic acid (A-CA) after treatment failure on amoxycillin
Trial: 28161079
Drug: Active RFc
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active RFc therapy (90 J/cm2)
Trial: 28161079
Drug: Sham RFc
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham RFc therapy (1 J/cm2)
Trial: 25599275
Drug: 1000 g
RxNorm normalized name: MENTHOL 80 g in 1000 g TOPICAL GEL [ACTIVICE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 g fish and mussels/week for 26 weeks (50 μg selenium/day)
Trial: 21110034
Drug: Randomized music
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized music therapy (classical, relaxing modern, smooth jazz)
Trial: 16798785
Drug: 0.03% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus ointment (TAC-O)
Trial: 16798785
Drug: 1% hydrocortisone
RxNorm normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1% hydrocortisone acetate (HA) and 0.1% hydrocortisone butyrate ointment (HC-O)
Trial: 11819709
Drug: Moxibustion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion with herbal medicine
Trial: 8473676
Drug: Combination TAO
RxNorm normalized name: troleandomycin
DrugBank: Troleandomycin (DB13179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination TAO and methylprednisolone (MPn)
Trial: 8473676
Drug: Combination TAO
RxNorm normalized name: troleandomycin
DrugBank: Troleandomycin (DB13179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination TAO and prednisone
Trial: 3936866
Drug: Sandoglobulin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandoglobulin (12 g as a 3% solution on day 0, day 5, and day 12, total of 36 g)
Trial: 27292543
Drug: Timed bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed bright light therapy
Trial: 27292543
Drug: Both timed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both timed bright light therapy and bedtime melatonin
Trial: 21039348
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2 mg) twice per day
Trial: 16372264
Drug: Vaccine candidate
RxNorm normalized name: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate
DrugBank: FINLAY-FR-1 (DB16524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine candidate genes OmpA and FepA
Trial: 6415987
Drug: Oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoclopramide from day 1 to 6
Trial: 6415987
Drug: Bromocriptine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine treatment from day 1 to 3
Trial: 31529295
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (200 μgr daily for 1 year)
Trial: 24560477
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol (400 mcg)
Trial: 22412143
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg orally twice a day with capecitabine 1,000 mg/m(2) orally twice a day for days 1 to 14 of every 21-day cycle
Trial: 22412143
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with capecitabine 1,000 mg/m(2) orally twice a day for days 1 to 14 of every 21-day cycle
Trial: 22412143
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg orally twice a day
Trial: 16234523
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (vincristine, cisplatin, cyclophosphamide, and etoposide)
Trial: 16234523
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (vincristine, carboplatin, ifosfamide, and etoposide)
Trial: 16234523
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (both regimens)
Trial: 7523131
Drug: Prednisone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (5 mg 4 times daily)
Trial: 7523131
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg 3 times daily)
Trial: 7523131
Drug: Estramustine phosphate
RxNorm normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estramustine phosphate (280 mg 2-3 times daily)
Trial: 7523131
Drug: Epirubicin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (100 mg/m2 i.v. every 3rd week)
Trial: 7523131
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (all drugs)
Trial: 61389
Drug: Methandienone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methandienone (100 mg/day for 6 weeks)
Trial: 25772701
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg preoperatively and 200 mg postoperatively on the day of surgery, continued at 200 mg three times daily for two days.
Trial: 11168342
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acid supplementation (2.08 g for 21 days)
Trial: 9294377
Drug: Amphetamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine treatment for 15 months
Trial: 9294377
Drug: Amphetamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine treatment
Trial: 25759106
Drug: Hydration with
RxNorm normalized name: Gold Bond Healing Hydration with Aloe Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration with isotonic saline (1 ml/kg/h since the beginning of the procedure and for 24 hours after it)
Trial: 21734179
Drug: 4-aminopyridine (4AP)
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (4AP) 5 mg 3 times daily
Trial: 10486353
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg twice daily for 24 months
Trial: 10486353
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily for 24 months
Trial: 2006663
Drug: Diuretics and
RxNorm normalized name: Low-ceiling diuretics and potassium-sparing agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics and methyldopa
Trial: 7168635
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term prophylaxis with a single intravenous dose of tobramycin and lincomycin
Trial: 31352415
Drug: Postextubation medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postextubation medical therapy (azithromycin 250 mg and budesonide 0.5 mg for 14 days)
Trial: 31352415
Drug: Postextubation medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postextubation medical therapy (azithromycin and inhaled budesonide)
Trial: 28069467
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of pantoprazole twice daily and diet changes for 3 months
Trial: 28069467
Drug: Treatment (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (pantoprazole and diet changes)
Trial: 21498312
Drug: Body weight-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body weight-adapted CM injection protocol (0.9 mL CM (370 mg I/mL) per kg during 12 s resulting in a constant injection dose rate of 28 mg I/kg/s)
Trial: 21498312
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose CM injection protocol (65 mL CM (370 mg I/mL) at 5 mL/s)
Trial: 10925979
Drug: 500‐mg Rowasa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500‐mg Rowasa (mesalamine) suppository
Trial: 8923784
Drug: Regimen I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen I: 400 mg of MST-16 combined with 25 mg of VP-16 administered daily
Trial: 8923784
Drug: Regimen II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen II: 400 mg of MST-16 combined with 25 mg of VP-16 administered intermittently (3 days a week or every other day)
Trial: 1376177
Drug: i.v. polyimmune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. polyimmune gammaglobulin (500 mg/kg) within 3 days of transplant with 250 mg/kg at weeks 1, 2, 4, and 6
Trial: 1376177
Drug: Monoclonal anti‐CD‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal anti‐CD‐3 therapy
Trial: 6377851
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of 40 mg of mixed gangliosides for ALS for six months
Trial: 6377851
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of 40 mg of mixed gangliosides for diabetic neuropathy for three months
Trial: 29140142
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (0.09 g·kg‐1)
Trial: 29140142
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee (0.09 g·kg‐1)
Trial: 20386344
Drug: E2 alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 alone (transdermal E2 0.72 mg for 2 days)
Trial: 20386344
Drug: E2 +
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 + DNG (E2 0.72 mg + DNG 2 mg/d for 1 week)
Trial: 20386344
Drug: E2 +
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 + MPA (E2 0.72 mg + MPA 2.5 mg/d for 1 week)
Trial: 14602753
Drug: r-hGH (0.067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hGH (0.067 mg/kg.d)
Trial: 9408810
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg/day or 1 mg/day
Trial: 8329024
Drug: CB0006 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB0006 at 0.1 mg/kg
Trial: 8329024
Drug: CB0006 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB0006 at 1 mg/kg
Trial: 8329024
Drug: CB0006 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB0006 at 5 mg/kg
Trial: 4036826
Drug: Dipyridamole infusion
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole infusion (0.14 mg/kg/min for 4 minutes)
Trial: 24814231
Drug: IN dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN dexmedetomidine (1 μg/kg) with midazolam premedication
Trial: 24814231
Drug: IN fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IN fentanyl (2 μg/kg) with midazolam premedication
Trial: 24814231
Drug: IN dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN dexmedetomidine (1 μg/kg) without premedication
Trial: 24814231
Drug: IN fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IN fentanyl (2 μg/kg) without premedication
Trial: 19076177
Drug: Immediate/early loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate/early loading of zygomatic implants
Trial: 19076177
Drug: Regular implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular implants
Trial: 18441038
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (9 minutes of electrical stimulation on the dorsiflexor muscles and 15 minutes of inhibitory Bobath techniques)
Trial: 16160622
Drug: Aripiprazole (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (initial dose 2 mg/d, titrated to 5, 10, or 15 mg/d)
Trial: 12969190
Drug: IFN TIW
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN TIW (5 MU thrice weekly for 8 weeks followed by 3 MU TIW for 40 weeks)
Trial: 12969190
Drug: IFN QD
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN QD (5 MU daily for 8 weeks followed by 3 MU QD for 16 weeks followed by 3 MU TIW for 24 weeks)
Trial: 10397076
Drug: BCAA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA treatment (200 ml of BCAA-rich solution daily for 7 days)
Trial: 10397076
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (TRH; protirelin)
Trial: 19633850
Drug: PI-88 delivered
RxNorm normalized name: Heparanase inhibitor PI-88
DrugBank: Muparfostat (DB05808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI-88 delivered subcutaneously (SC) at doses ranging from 80 to 315 mg
Trial: 18451646
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg once daily for 2 weeks
Trial: 10993128
Drug: Clomipramine (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (50-150 mg)
Trial: 9126791
Drug: Hepatitis G
RxNorm normalized name: Hepatitis G antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis G virus infection
Trial: 9126791
Drug: Hepatitis G
RxNorm normalized name: Hepatitis G antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis G virus positive patients
Trial: 1541312
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release tablets once daily (o.m.)
Trial: 1541312
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release tablets twice daily (b.d.)
Trial: 1541312
Drug: Plain tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain tablets twice daily (b.d.)
Trial: 1541312
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release tablets
Trial: 3157887
Drug: Capillary protective
RxNorm normalized name: Artemisia capillaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capillary protective drug derived from rutin
Trial: 30846294
Drug: Ablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative fractional CO2 laser (AFCO2L) treatment
Trial: 26811679
Drug: Paliperidone-ER (3-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone-ER (3-12 mg/day)
Trial: 20441572
Drug: Diabetes-specific cognitive
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes-specific cognitive behavioural therapy adapted for the elderly
Trial: 20441572
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment as usual
Trial: 20441572
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment conditions after 12 weeks
Trial: 12139152
Drug: Oral vaccine
RxNorm normalized name: RotaTeq Oral Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vaccine prepared from insect saliva
Trial: 12139152
Drug: Placebo (stable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (stable vaccine solvent)
Trial: 9923552
Drug: UFT 300
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 300 mg/m2 per day plus LV 90 mg per day in three divided doses every 8 h for 28 days
Trial: 9923552
Drug: Oral LV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral LV 30 mg plus UFT 200 mg
Trial: 8635038
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (r‐HuEPO) administered subcutaneously at a dose of 150 U/kg three times per week for 6 weeks; in nonresponders, the dose was doubled for the subsequent 6 weeks.
Trial: 1871856
Drug: CyA monotherapy
RxNorm normalized name: CyA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA monotherapy
Trial: 6352600
Drug: Azlocillin at
RxNorm normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azlocillin at 18 g/day for a mean of 13 days
Trial: 6352600
Drug: Gentamicin at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin at 180 mg/day for a mean of 11 days
Trial: 30277424
Drug: Anchored to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anchored to a four-times-daily treatment regimen
Trial: 29735964
Drug: Thunder-fire moxibustion
RxNorm normalized name: Fire Out
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thunder-fire moxibustion therapy combined with calcium carbonate D3
Trial: 17609305
Drug: Ablative target-absorbed
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative target-absorbed dose of 200 Gy (n = 78)
Trial: 17609305
Drug: Nonablative doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonablative doses of 100 or 120 Gy (n = 99)
Trial: 15640479
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein containing 99 mg isoflavones/d
Trial: 15640479
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein containing 99 mg isoflavones/d (in equol producers)